US2017247319A1PendingUtilityA1

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability

52
Assignee: SANOFI SAPriority: Sep 18, 2009Filed: Oct 11, 2016Published: Aug 31, 2017
Est. expirySep 18, 2029(~3.1 yrs left)· nominal 20-yr term from priority
Inventors:Gerrit Hauck
A61P 35/00A61P 37/00A61P 37/08A61P 37/06A61P 7/00A61P 35/02A61P 37/02A61P 31/00A61P 29/00A61P 27/02A61P 3/02A61P 31/04A61P 25/00A61P 19/02A61P 19/04A61P 17/06A61P 11/02A61P 17/00A61P 11/06C07C 255/44A61K 9/2054A61K 31/277A61K 9/2013A61K 9/2059A61K 47/36A61K 9/16A61K 9/20
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.

Claims

exact text as granted — not AI-modified
I claim: 
     
         1 . A solid pharmaceutical composition comprising a therapeutically effective amount of teriflunomide or a pharmaceutically acceptable basic addition salt thereof, wherein the solid pharmaceutical composition does not contain colloidal silicon dioxide.

Join the waitlist — get patent alerts

Track US2017247319A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.